

**BLAU FARMACÊUTICA S.A.**

Publicly Held Company  
NIRE 35.300.416.406  
CVM Code No. 2462-7

**MATERIAL FACT**

**Request for Exceptional Treatment with Respect to Compliance with the Minimum Percentage of Outstanding Shares**

A BLAU FARMACÊUTICA S.A. (Ticker: BLAU3; "Blau" or "Company"), in compliance with the provisions of CVM Resolution No. 44, of August 23, 2021, as amended, and in addition to the Material Facts disclosed on April 14, 2021, June 6, 2022, September 22, 2023 and October 10, 2023, hereby informs its shareholders and the market in general that, in response to a new request for exceptional treatment with regard to compliance with the minimum percentage of outstanding shares ("Free Float") established in Article 10 of the Novo Mercado Regulation, formulated by the Company on November 13, 2024, B3 S.A. – Brasil, Bolsa, Balcão ("B3") granted, on an extraordinary basis, authorization for the Company to maintain, in free circulation, at least, shares representing 16.55% of its capital stock, corresponding to the percentage currently in circulation, until its recomposition, which must occur by June 30, 2026, provided that, if the free float reaches a level higher than 16.55%, at any time during the term granted by B3, its reduction will not be allowed until the minimum percentage of 20% is reached, defined in the Novo Mercado Regulation ("Authorization").

To this end, the Company shall maintain the counterparts previously established in the Letters 144/2021-DIE of 14.04.2021, 352/2023-DIE of 06.10.2023 and 410/2023-DIE of 11.16.2023. The counterparts are available for consultation on the B3 website through the link: [https://www.b3.com.br/pt\\_br/regulacao/regulacao-de-emissores/condicoes-excepcionais/](https://www.b3.com.br/pt_br/regulacao/regulacao-de-emissores/condicoes-excepcionais/).

Cotia, December 13, 2024

**Douglas Leandro Rodrigues**  
**Chief Financial and Investor Relations Officer**

**About Blau Farmacêutica (BLAU3):**

Blau is a leading pharmaceutical industry in the institutional segment and a pioneer in biotechnology, with an owned brands portfolio of highly complex drugs focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, infectiology, operating in different therapeutic classes. Blau has a continental footprint, present in 7 countries in Latin American – Brazil, Argentina, Colombia, Chile, Ecuador, Peru, Uruguay – and the United States, and has a modern pharmaceutical industrial complex in Brazil, composed of five industrial facilities, with state-of-the-art technology, dedicated to the production of biological and synthetic products.